R&D News | pharmaphorum

News

Sanofi/Regeneron’s Dupixent shows more promise in nasal poly...

Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP

News

Novartis licenses lipoprotein-lowering CVD drug

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elev

News

AbbVie upscales Voyager alliance with new target, more cash

AbbVie has extended its collaboration with gene therapy specialist Voyager Therapeutics, adding a new programme in Parkinson’s disease and another $1.5 billion in potential fees.

News

Cell therapy produces encouraging first results in eye trial

UK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa (RP).

News

Merck adds to I-O stable with $300m Immune Design buy

Just a few months after Immune Design saw its shares crater on a phase II fail, Merck & Co/MSD has agreed a deal to acquire the biotech and its immuno-oncology and vaccines pipeline.

News

Patients switch to lower dose of Pfizer's RA pill after safe...

Pfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in a clinical study, after a safety signal emerged in the trial of patie

Sanofi/Regeneron’s Dupixent shows more promise in nasal poly...

Novartis licenses lipoprotein-lowering CVD drug

AbbVie upscales Voyager alliance with new target, more cash

Cell therapy produces encouraging first results in eye trial

Merck adds to I-O stable with $300m Immune Design buy

Patients switch to lower dose of Pfizer's RA pill after safe...

AZ boosts vaccine capabilities with Omniose buy

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks